Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zipp

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Scandinavian Journal of Rheumatology|August 23, 2008
Multiple sclerosis following etanercept treatment for ankylosing spondylitisC F Pfueller, E Seipelt, F Zipp, et al.
Der Nervenarzt|February 1, 1997
[Multiple sclerosis. New therapeutic strategies in the experimental stage]F Zipp, N Sommer, M Rösener, et al.
Der Nervenarzt|December 1, 1996
[Neurologic side-effects of pharmacologic corticoid therapy]M Rösener, E Martin, F Zipp, et al.
Journal of Neuroimmunology|February 16, 2000
Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells--implications for multiple sclerosisU Wendling, O Aktas, K Schmierer, et al.
Der Nervenarzt|June 1, 1996
[Influence of genetic factors on multiple sclerosis]N Sommer, F Zipp, M Rösener, et al.
Journal of Neuroimmunology|July 15, 1998
Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosisF Zipp, K Otzelberger, J Dichgans, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2007
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisF Paul, J Dörr, J Würfel, et al.
Neurology|September 26, 2001
Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patientsJ D Lünemann, O Aktas, P Gniadek, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 18, 2002
Rhabdomyolysis during interferon-beta 1a treatmentJ D Lünemann, B Schwarzenberger, N Kassim, et al.
BMJ Case Reports|July 8, 2011
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisF Paul, J Dörr, J Würfel, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Scandinavian Journal of Rheumatology|August 23, 2008
Multiple sclerosis following etanercept treatment for ankylosing spondylitisC F Pfueller, E Seipelt, F Zipp, et al.
Der Nervenarzt|February 1, 1997
[Multiple sclerosis. New therapeutic strategies in the experimental stage]F Zipp, N Sommer, M Rösener, et al.
Der Nervenarzt|December 1, 1996
[Neurologic side-effects of pharmacologic corticoid therapy]M Rösener, E Martin, F Zipp, et al.
Journal of Neuroimmunology|February 16, 2000
Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells--implications for multiple sclerosisU Wendling, O Aktas, K Schmierer, et al.
Der Nervenarzt|June 1, 1996
[Influence of genetic factors on multiple sclerosis]N Sommer, F Zipp, M Rösener, et al.
Journal of Neuroimmunology|July 15, 1998
Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosisF Zipp, K Otzelberger, J Dichgans, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2007
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisF Paul, J Dörr, J Würfel, et al.
Neurology|September 26, 2001
Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patientsJ D Lünemann, O Aktas, P Gniadek, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 18, 2002
Rhabdomyolysis during interferon-beta 1a treatmentJ D Lünemann, B Schwarzenberger, N Kassim, et al.
BMJ Case Reports|July 8, 2011
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosisF Paul, J Dörr, J Würfel, et al.
Pageof 9